Literature DB >> 18973464

Development and validation of a high-performance liquid chromatography assay for posaconazole utilizing solid-phase extraction.

Dominic Störzinger1, Stefanie Swoboda, Christoph Lichtenstern, Carsten Müller, Markus A Weigand, Torsten Hoppe-Tichy.   

Abstract

BACKGROUND: Posaconazole is a new broad-spectrum triazole antifungal drug that is used in prophylaxis and therapy of opportunistic fungal infections in immunocompromised patients. Up to now, it is available as an oral suspension only. Due to variable systemic availability known from other azoles, such as itraconazole, it is important to measure blood levels, especially in patients undergoing abdominal surgery which may influence the intestinal resorption.
METHODS: A sensitive and selective high-performance liquid chromatography method for the precise determination of posaconazole and the internal standard clotrimazole in human plasma was developed and validated. Samples were extracted using solid-phase extraction and separated on a reversed-phase C8 column (150 x 4.6 mm, 5 microm) using phosphate buffer (pH 6.7, 0.04 M):acetonitrile:methanol (43:49:8, v/v/v) as mobile phase. UV detection was performed at 260 nm.
RESULTS: This method showed that a lower limit of quantification was 50 ng/mL and the limit of detection 3 ng/mL. Linearity was tested in the range from 50 to 5000 ng/mL (r(2)=0.9998). Mean recovery was 86%.
CONCLUSIONS: The method proved to be a useful tool for therapeutic drug monitoring. It is specific, precise and showed excellent reproducibility as well as a favourable accuracy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18973464     DOI: 10.1515/CCLM.2008.338

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  6 in total

1.  Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma.

Authors:  Lorena Baietto; Antonio D'Avolio; Giusi Ventimiglia; Francesco Giuseppe De Rosa; Marco Siccardi; Marco Simiele; Mauro Sciandra; Giovanni Di Perri
Journal:  Antimicrob Agents Chemother       Date:  2010-06-07       Impact factor: 5.191

2.  Plasma concentrations of posaconazole administered via nasogastric tube in patients in a surgical intensive care unit.

Authors:  Dominic Störzinger; Stephan Borghorst; Stefan Hofer; Cornelius J Busch; Christoph Lichtenstern; Georg Hempel; Markus A Weigand; Torsten Hoppe-Tichy
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

3.  Relevance of timing for determination of posaconazole plasma concentrations.

Authors:  Werner J Heinz; Janina Zirkel; Anna Kuhn; Diana Schirmer; Ulrike Lenker; Daniela Keller; Hartwig Klinker
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

4.  Multicenter comparison of the ISO standard 20776-1 and the serial 2-fold dilution procedures to dilute hydrophilic and hydrophobic antifungal agents for susceptibility testing.

Authors:  Alicia Gomez-Lopez; Maiken Cavling Arendrup; Cornelia Lass-Floerl; Juan-Luis Rodriguez-Tudela; Manuel Cuenca-Estrella
Journal:  J Clin Microbiol       Date:  2010-03-10       Impact factor: 5.948

5.  Instrument parameters controlling retention precision in gradient elution reversed-phase liquid.

Authors:  Ayse Beyaza; Wenzhe Fana; Peter W Carr; Adam P Schellinger
Journal:  J Chromatogr A       Date:  2014-12-05       Impact factor: 4.759

6.  A Comparative Study of Newly Developed HPLC-DAD and UHPLC-UV Assays for the Determination of Posaconazole in Bulk Powder and Suspension Dosage Form.

Authors:  Dalia A Hamdy; Tarek S Belal
Journal:  J Anal Methods Chem       Date:  2014-09-03       Impact factor: 2.193

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.